Adma Biologics reported $204.41M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Adma Biologics USD 204.41M 121.28M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Omeros USD 442.16M 199K Sep/2023
Takeda JPY 4.94T 58.13B Jun/2026